Finding a 'Win-Win-Win Situation'

Dr. Holger Franke, head of Technical Department, Klaus F. Meyer
Dr. Holger Franke, head of Technical Department, Klaus F. Meyer

What kind of growth do you aspire to in the next few years; in which sectors, markets or regions do you see significant growth opportunities?

Klaus F. Meyer aspires to an organic growth in the next years. We are focusing in the European markets as well as emerging markets, especially China, India and Russia.

Our main target markets are pharma and agro chemicals. Especially in the latter one, we expect rising demands for our products because of strong needs for agricultural chemicals in the world.

How do you intend to implement these plans and seize these opportunities?

Together with our costumers we are running projects for new products and new developments. Having good relationships with our main costumers as well as our main producers, we see ourselves as an interface for both of them.

We have already identified some new possibilities, which we discuss with both sides to get a powerful win-win-win situation for all three participating partners.

 

 

Company contact







CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.